Learning clinical trials

Explore recruiting learning clinical trials.

Recruiting learning studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Learning trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Targeted glucocorticoid administration to improve safety learning in posttraumatic stress disorder patients with HPA axis dysregulation

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Oxytocin and attachment development: Looking beyond the expected?

Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Experimental Study on Alcohol Use and Behavior in Young Adults

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma

Norway, Denmark, Netherlands, Spain, France, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of 24IU of intranasally administered oxytocin

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Learning trials by city

Learning in Toronto Learning in Vancouver Learning in Montreal Learning in Calgary Learning in Edmonton Learning in Ottawa Learning in Winnipeg Learning in Quebec City Learning in Hamilton Learning in Kitchener Learning in London Learning in Halifax Learning in New York Learning in Los Angeles Learning in Chicago Learning in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease